SCOTUS reverses Federal Circuit in Life Technologies v Promega

The US Supreme Court today ruled that supplying a single component of a multi-component invention for manufacture abroad does not constitute patent infringement.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Federal Circuit reverses its earlier ruling in Life Technologies v Promega

14 November 2017 The US Court of Appeals for the Federal Circuit has reversed its findings in Life Technologies v Promega, nine months after the US Supreme Court limited overseas patent infringement.

Americas

Life Technologies v Promega to be heard at US Supreme Court

5 December 2016 Oral arguments in Life Technologies v Promega are due to take place tomorrow in the US Supreme Court to determine whether the US Court of Appeals for the Federal Circuit correctly defined “substantial portion”.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

SCOTUS reverses Federal Circuit in Life Technologies v Promega

More on this story

Editor's picks

Editor's picks

More features